Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia.
Leuk Res
; 38(2): 236-42, 2014 Feb.
Article
in En
| MEDLINE
| ID: mdl-24280282
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrazoles
/
Bone Marrow
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Antineoplastic Combined Chemotherapy Protocols
/
Drug Resistance, Neoplasm
/
Protein Kinase Inhibitors
Limits:
Humans
Language:
En
Journal:
Leuk Res
Year:
2014
Document type:
Article